Navigation Links
NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
Date:4/29/2009

otection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of NeurogesX' product candidates and the advantages of NeurogesX' product candidates over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission. 

    NeurogesX, Inc.                         The Ruth Group
    Stephen Ghiglieri                       Sara Ephraim (investors)
    Chief Financial Officer                 (646) 536-7002
    (650) 358-3310                          sephraim@theruthgroup.com

                                            Janine McCargo (media)
                                            (646) 536-7033
                                            jmccargo@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
2. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
3. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
4. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
5. NeurogesX Reports Third Quarter 2008 Results
6. NeurogesX to Report Third Quarter 2008 Financial Results
7. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
8. NeurogesX Responds to EMEAs Day 120 Questions
9. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
10. NeurogesX Reports Second Quarter 2008 Results
11. NeurogesX to Report Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013  Dr. Gerald Zon ... acid research, recently launched a new blog in conjunction ... ( zon.trilinkbiotech.com ), focuses on what,s trending in the ... industry thought leaders, discussions of research presented at conferences ... Dr. Zon (PhD Princeton University 1971) developed ...
(Date:5/20/2013)... Md. and BALTIMORE , May 20, ... a regional private-public partnership focusing on commercializing market-relevant ... in Central Maryland , today ... as the first Entrepreneur-in-Residence (EIR) for BHI at ... Heart, Lung and Blood Institute (NHLBI). Dr. ...
(Date:5/20/2013)... BOSTON , May 20, 2013 Rhythm ... clinical trial of RM-131, the company,s novel ghrelin agonist ... diabetic patients. The trial demonstrated that RM-131 significantly accelerates ... in type 1 diabetic patients with diabetic gastroparesis. The ... conference in Orlando and recently ...
(Date:5/20/2013)... 2013 Recognizing exciting and innovative ... to its 2013 Class of Young Professors. ... provide this outstanding international group with more than ... science to meet global challenges.     , The DuPont ... young and untenured research faculty working in areas ...
Breaking Biology Technology:Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3
... Leaders Join Forces to Promote Early Detection ... and Treatment of Hypertension in the UK, ... Ltd. (Tel Aviv Stock Exchange: INCR), and Omron Healthcare (UK),Ltd., ... to strengthen the link between hypertension diagnostics and,therapies in the ...
... Blood found 92 percent reduction in ... incidence ... a rare,blood disorder called PNH experienced a 92 percent reduction ... (eculizumab), according to an analysis of clinical studies,recently published online ...
... 20 - Essential, Structure-Searchable Chemistry ... to Researchers Elsevier Information Systems GmbH, ... of scientific, technical and medical information,is pleased ... the CrossFire Beilstein,database will contain more than ...
Cached Biology Technology:InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom 2InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom 3InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom 4PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 2PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 3PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 4PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 5PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 6PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 7PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 8CrossFire Beilstein Database Exceeds Ten Million Compounds 2CrossFire Beilstein Database Exceeds Ten Million Compounds 3
(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...
(Date:5/20/2013)... Science Foundation (NSF) planning grant will help establish the ... program of the University of Illinois at Urbana-Champaign and ... will be devoted to research in drying moist, porous ... and paper products; chemical products; textiles; and biopharmaceuticals," said ... science and human nutrition and the Illinois site director. ...
(Date:5/19/2013)... a strain of electricity-producing bacteria that can grow using ... dioxide as its sole source of carbon. Researchers ... at the 113th General Meeting of the American Society ... current production solely on hydrogen," says Amit Kumar, a ... are part of the Lovley Lab Group at the ...
Breaking Biology News(10 mins):Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3NSF approves planning grant for Center for Advanced Research in Drying 2
... Fla. (June 16, 2009) To determine if guided ... and functional recovery, researchers at the University of Pittsburgh ... the injured peripheral nerves of laboratory rats. ... shown to be an abundant source of post-natal precursor ...
... engineers have taken a first step toward a minimally ... heat administered from the end of a catheter. ... possible to treat brain tumors without the side effects ... or radiation. The bioengineers designed and built an ...
... University of California, Berkeley, researchers have found what they ... of the puzzle about how stress causes sexual dysfunction ... of stress hormones - glucocorticoids such as cortisol - ... hormone (GnRH), and subsequently suppresses sperm count, ovulation and ...
Cached Biology News:Peripheral nerve repair with fat precursor cells led to wider nerves and less muscle atrophy 2Potential for non-invasive brain tumor treatment 2Stress puts double whammy on reproductive system, fertility 2Stress puts double whammy on reproductive system, fertility 3
... linear ion trap mass spectrometer enables high-throughput ... The LXQ linear ion trap mass spectrometer ... applications, delivering the fast cycle time and ... trap at an attractive price. The ...
... developed specifically for reduced mutagenicity to be ... agarose or acrylamide gels. SYBR Safe stain is ... SYBR Safe stain's detection sensitivity is better than ... as a premixed solution that can be used ...
... These are just some the things youll ... of Protein-Protein Interactions, edited by Erica Golemis, One ... skillfully edited compilation of topics in protein interaction ... text that must be a part of your ...
... This exceptionally sensitive nucleic acid gel stain ... low background in gels, making it ideal for ... standard UV transilluminators. SYBR Green I nucleic ... in capillary electrophoresis, real-time PCR assays and bandshift ...
Biology Products: